logo image
  • News
    • People Moves
    • Deal Wins
    • Demand Drivers
    • M&A and Funding
    • Financial Results
    • Technology
    • Academia
    • Industry News
    • Features
    • Machine Translation
    • — Divider —
    • Slator Pro
    • — Divider —
    • Press Releases
    • Sponsored Content
  • Data & Research
    • Research Reports & Pro Guides
    • Language Industry Investor Map
    • Real-Time Charts of Listed LSPs
    • Language Service Provider Index
  • Podcasts & Videos
  • Events
    • SlatorCon Remote May 2021
    • Email Marketing for Freelance Linguists
    • Preparing for the Critical Google Update Coming in May 2021
    • — Divider —
    • SlatorCon Coverage
    • Other Events
  • Directory
  • RFP Center
  • Jobs
MENU
  • News
    • People Moves
    • Deal Wins
    • Demand Drivers
    • M&A and Funding
    • Financial Results
    • Technology
    • Academia
    • Industry News
    • Features
    • Machine Translation
    • — Divider —
    • Slator Pro
    • — Divider —
    • Press Releases
    • Sponsored Content
  • Data & Research
    • Research Reports & Pro Guides
    • Language Industry Investor Map
    • Real-Time Charts of Listed LSPs
    • Language Service Provider Index
  • Podcasts & Videos
  • Events
    • SlatorCon Remote May 2021
    • Email Marketing for Freelance Linguists
    • Preparing for the Critical Google Update Coming in May 2021
    • — Divider —
    • SlatorCon Coverage
    • Other Events
  • Directory
  • RFP Center
  • Jobs

Register For Email Marketing for Freelance Linguists and Learn How To Win New Clients.

  • Slator Market Intelligence
  • Slator Advertising Services
  • Slator Advisory
  • Login
Search
Generic filters
Exact matches only
Advertisement
Translation Fail Puts Chinese Pharma Company in US Regulator’s Crosshairs

3 years ago

November 9, 2017

Translation Fail Puts Chinese Pharma Company in US Regulator’s Crosshairs

Industry News ·

by Eden Estopace

On November 9, 2017

3 years ago
Industry News ·

by Eden Estopace

On November 9, 2017

Translation Fail Puts Chinese Pharma Company in US Regulator’s Crosshairs

The life sciences are among the fastest growing industry verticals in language services and the flavor du jour in language industry M&A. What’s driving demand is the continued growth of the pharma and medical device markets as well as the fact that few other industries require higher quality and process standards from LSPs and translators alike.

The regulatory requirements are stringent. A recent case involving a Chinese company and the US regulator again highlights translation’s critical role in the pharma supply chain. For failing to translate a drug label properly, a Chinese drug manufacturer based in Guangdong Province received a warning letter from the US Food and Drug Administration (FDA).

The letter dated October 30, 2017 shows that Guangdong Zhanjiang Jimin Pharmaceutical Co. violated regulations for finished pharmaceuticals when it labeled an over-the-counter drug exported to the US as containing the ingredient hydrocortisone.

Advertisement

“When our investigator inquired about the incorrect API, your firm stated that there was a translation mistake”

The correct active pharmaceutical ingredient (API) was dexamethasone acetate.

“When our investigator inquired about the incorrect API, your firm stated that there was a translation mistake, and the two APIs were believed to be the same ingredient,” the letter noted.

The drug in question, Piyanping Anti-Itch Lotion, was recalled in the US on August 30, 2017. The FDA, however, said that the drug manufacturer failed to provide an action plan to prevent a recurrence.

The US regulator strongly recommended that the Guangdong-based drugmaker engage a consultant to assist the company in meeting the requirements of current good manufacturing practice (CGMP) regulations.

China’s Pharma Market Evolving Fast

Translation is becoming ever more important to the pharmaceutical industry in China, especially in clinical research. And it is not the US regulator alone that is providing the impetus for companies to get translations done right.

In 2016, Slator reported that China has embarked on the biggest regulatory overhaul of its pharmaceutical industry in more than 15 years. Part of the reforms is the launch of 22 new policies and the revision of China’s Drug Administration Law.

The China Food and Drug Administration (CFDA) also issued new directives on translation requirements for registering medical devices in the Chinese market.

In March 2017, Maija Burtmanis, an Australian qualified senior Legal/compliance Life Sciences Professional, spoke at a Slator roundtable in Singapore to discuss compliance and vendor management in clinical trials.

“From a legal perspective, if there is one thing we must be concerned about, it is how to get the interpretation of the language right,” she said.

Finally, China recently declared it was going to accept foreign clinical trial data in its drug approval process, which likely means additional translation requirements from international pharma companies seeking to market their products in China.

TAGS

Chinalife sciencespharmapharmaceuticalpharmaceutical industrypharmaceutical translationstranslation
SHARE
Eden Estopace

By Eden Estopace

IT journalist and Online Editor at Slator. Loves books, movies, and gadgets; writes for a living, but codes for fun.

Advertisement

SUBSCRIBE TO THE SLATOR WEEKLY

Language Industry Intelligence
In Your Inbox. Every Friday

SUBSCRIBE

SlatorSweepSlatorPro
ResearchRFP CENTER

PUBLISH

PRESS RELEASEDIRECTORY LISTING
JOB ADEVENT LISTING

Bespoke advisory including speaking, briefings and M&A

SLATOR ADVISORY
Advertisement

Featured Reports

See all
Slator 2020 Language Industry M&A and Funding Report

Slator 2020 Language Industry M&A and Funding Report

by Slator

Slator 2021 Data-for-AI Market Report

Slator 2021 Data-for-AI Market Report

by Slator

Slator 2020 Medtech Translation and Localization Report

Slator 2020 Medtech Translation and Localization Report

by Slator

Pro Guide: Sales and Marketing for Language Service Providers

Pro Guide: Sales and Marketing for Language Service Providers

by Slator

Press Releases

See all
Iconic Launches INTRA Translation Platform

Iconic Launches INTRA Translation Platform

by Iconic

Pangeanic Is Now Certified to ISO 27001 Information Security

Pangeanic Is Now Certified to ISO 27001 Information Security

by Pangeanic

VSI Acquires Leading Brazilian Dubbing Studio, Vox Mundi

VSI Acquires Leading Brazilian Dubbing Studio, Vox Mundi

by VSI

Upcoming Events

See All
  1. Smartling - Global Ready Conference 2021

    Global Ready Conference

    by Smartling

    · April 14

    When you can't traverse the world, let the world come to you. Join our annual global event from home.

    More info FREE

Featured Companies

See all
Sunyu Transphere

Sunyu Transphere

Text United

Text United

Memsource

Memsource

Wordbank

Wordbank

Protranslating

Protranslating

Seprotec

Seprotec

Versacom

Versacom

Smartling

Smartling

XTM International

XTM International

Translators without Borders

Translators without Borders

STAR Group

STAR Group

memoQ Translation Technologies

memoQ Translation Technologies

Advertisement

Popular articles

Poland Rules on LSP Using Google Translate; Defines ‘Professional Translator’

Poland Rules on LSP Using Google Translate; Defines ‘Professional Translator’

by Marion Marking

Behind the Scenes of the European Parliament’s Pivot to Remote Interpreting

Behind the Scenes of the European Parliament’s Pivot to Remote Interpreting

by Seyma Albarino

Why Netflix Shut Down Its Translation Portal Hermes

Why Netflix Shut Down Its Translation Portal Hermes

by Esther Bond

SlatorPod: The Weekly Language Industry Podcast

connect with us

footer logo

Slator makes business sense of the language services and technology market.

Our Company

  • Support
  • About us
  • Terms & Conditions
  • Privacy Policy

Subscribe to the Slator Weekly

Language Industry Intelligence
In Your Inbox. Every Friday

© 2021 Slator. All rights reserved.

Sign up to the Slator Weekly

Join over 13,500 subscribers and get the latest language industry intelligence every Friday

Your information will never be shared with third parties. No Spam.